As of now，Alphamab Oncology owns or co-owns 28 patents worldwide related to its technology platforms and product pipelines. The R&D team has published many research papers in influential journals.
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
view more
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
view more
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
view more
Engineering a Smart Agent for Enhanced Immunotherapy Effect by Simultaneously Blocking PD-L1 and CTLA-4
view more
